Home » Topics » BioWorld Science

BioWorld Science
RSS

TAS-4464 demonstrates potent antitumor activity in hematologic and solid tumor models

Sep. 4, 2019

Positive phase II data presented for CTP-543 in patients with alopecia areata

Sep. 4, 2019

Kura Oncology presents phase II results for tipifarnib in HRAS-mutant urothelial carcinoma

Sep. 4, 2019

Inhibrx announces phase I dose-escalation data for INBRX-109

Sep. 4, 2019

FDA clears IND application for phase I/II study of OBI-999

Sep. 4, 2019

Four-way interaction screen gives clues to drug effects

Sep. 4, 2019

Vulnerable brains can be steered towards healthy development

Sep. 4, 2019

Discovery and preclinical characterization of c-KIT kinase inhibitor CHMFL-KIT-64

Sep. 4, 2019

Targeted protein degradation with DGY-08-097 shows promise for hepatitis C virus treatment

Sep. 4, 2019

Boehringer Ingelheim to advance BI-456906 into phase II for obesity and diabetes

Sep. 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...